Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 7/20 | 0.42 |
| ▸ | FNTB | P49356 | 7/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9955563 | 0.84 | ALPI (0.43) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL83022 | 0.84 | ANPEP (0.35) | FNTAFNTBPGGT1BKMT2A | |
| SCHEMBL907397 | 0.84 | FNTA (0.47) | FNTAFNTBPGGT1B | |
| SCHEMBL2213322 | 0.82 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL2213310 | 0.82 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL9516223 | 0.81 | ALPI (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL10870312 | 0.81 | ALPI (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1128048 | 0.79 | ANPEP (0.50) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1394213 | 0.79 | SLC7A5 (0.38) | SLC7A5 | |
| SCHEMBL154435 | 0.78 | FNTA (0.34) | FNTAFNTBPGGT1BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814558-B1 | METHODS AND COMPOSITIONS FOR REDUCING NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS | YOO SEO HONG (US) | 2010-12-15 | — | — | EP | claimed |
| US-11618790-B2 | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-2655413-B1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | HOFFMANN LA ROCHE (CH) | 2019-01-16 | — | — | EP | disclosed |
| CN-104395340-B9 | Methods of customizing selective and multispecific therapeutic molecules comprising at least two different targeting entities and uses thereof | 弗·哈夫曼-拉罗切有限公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-104395340-B | Include the method and application thereof of at least two different target stereotropic customization selectivity and polyspecific treatment molecule | 弗·哈夫曼-拉罗切有限公司 | 2018-10-02 | — | — | CN | disclosed |
| EP-2867255-B1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | HOFFMANN-LA ROCHE INC. (US) | 2015-08-20 | — | — | US | disclosed |
| EP-2867255-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| CN-104395340-A | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof | HOFFMANN LA ROCHE | 2015-03-04 | — | — | CN | disclosed |
| WO-2014001326-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20130344094-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-26 | — | — | US | disclosed |
| EP-2655413-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085111-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130344094-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | ALPI 2416/4885PKM 1840/4885PTGS1 4661/4885 |
| US-20150232560-A1 | METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF | FCGR3B, VSIG8, CD47 | ALPI 3322/4885PKM 4646/4885PTGS1 4856/4885 |
| US-20200207874-A1 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY | PNKP, RNASE1, DCLRE1B | ALPI 2416/4885PKM 1840/4885PTGS1 4661/4885 |
| US-11618790-B2 | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery | PNKP, RNASE1, DCLRE1B | ALPI 2416/4885PKM 1840/4885PTGS1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.